Ibudilast

From MEpedia, a crowd-sourced encyclopedia of ME and CFS science and history
The printable version is no longer supported and may have rendering errors. Please update your browser bookmarks and please use the default browser print function instead.

Ibudilast (brand names Ketas or Pinatos in Japan, drug development names AV411 and MN166 the United States)) is a drug used for over 20 years in Japan, mostly for asthma and post-stroke dizziness.[1] Ibudilast is a phosphodiesterase inhibitor, an immunomodulator, reduces microglial activation, and has anti-inflammatory effects.[1]

Potential uses[edit | edit source]

Ibudilast is under investigation for a number of new purposes, and evidence exists that it can be combined with opioids to reduce chronic nerve pain.[1] Many studies of ibudilast are on rats or other animals rather than humans.[1] Ibudilast crosses the blood-brain barrier and suppresses glial cell activation.

Theory[edit | edit source]

Evidence[edit | edit source]

Clinicians[edit | edit source]

Risks and safety[edit | edit source]

Costs and availability[edit | edit source]

See also[edit | edit source]

Learn more[edit | edit source]

References[edit | edit source]

  1. 1.0 1.1 1.2 1.3 Rolan, P; Hutchinson, MR; Johnson, KW (December 2009). "Ibudilast: a review of its pharmacology, efficacy and safety in respiratory and neurological disease". Expert Opinion on Pharmacotherapy. 10 (17): 2897–2904. doi:10.1517/14656560903426189. ISSN 1465-6566.